drugset / Trial / NCT05038904

Preventing Anaphylaxis With Acalabrutinib

NCT05038904

Phase 2 Completed 10 enrolled Johns Hopkins University AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adults.

Timeline

Start
2021-12-16
Primary completion
2022-12-08
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg Oral

Indications